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Introduction
Colorectal cancer is the second most common 
cause of death due to malignant disease in Europe, 
and surgery remains a key part of its treatment [1]. 
The Enhanced Recovery After Surgery (ERAS) proto-
col was introduced into surgical practice more than 
a decade ago, and changed the clinical outcomes al-
most immediately [2–4].
Nonetheless, there is still room for improvement, 
particularly in case of rectal cancer. Its treatment 
depends on the location and stage; however, all pa-
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A b s t r a c t
Introduction: Protective loop ileostomy (PLI) is used to reduce the anastomotic leak rate after resection of the rec-
tum. It is an effective, yet burdensome procedure contradicting the aims of enhanced recovery after surgery (ERAS) 
by slowing down recovery. Early closure (EC) of the PLI has the potential to change the situation, and it should be-
come part of ERAS.
Aim: To analyze the effectiveness of EC in ERAS patients.
Material and methods: A randomized clinical trial was performed between October the 1st, 2016 and December the 
31st, 2017. Fifty-eight adult patients (24 females, 34 males, mean age: 55.7 and 56.2) operated on for rectal carci-
noma according to the ERAS protocol with PLI were randomly assigned to the late (L) or early (E) closure group (14 
days after discharge). Time to start adjuvant chemotherapy, complication rate, and health care costs were analyzed.
Results: There were no significant differences between groups regarding the length of surgery (83.2 ±15.9 vs. 87.1 
±21.7 min, in E and L, respectively), intraoperative blood loss (15.2 ±7.5 vs. 17.3 ±11.1 ml, respectively), median 
hospital stay, or the time to pass flatus and stool. The difference in the time needed to start the adjuvant treatment 
(38.7 ±5.7 vs. 33.2 ±5.8 days, p < 0.01), was compensated by the reduction of time living with a stoma (17.2 vs. 299.0 
days) and health care costs: (43.68 vs. 698.42 USD).
Conclusions: Early closure is a safe and effective therapeutic approach, improving the recovery. Therefore it should 
be implemented as part of the ERAS protocol for rectal cancer patients.
Key words: protective stomy, colorectal cancer, loop ileostomy.
General surgery
Stanisław Kłęk, Magdalena Pisarska, Katarzyna Milian-Ciesielska, Tomasz Cegielny, Ryszard Choruz, Jerzy Sałówka, Piotr Szybinski, Michał Pędziwiatr
436 Videosurgery and Other Miniinvasive Techniques 4, December/2018
tients with resectable tumors would undergo surgery 
either after neoadjuvant radio- and chemotherapy or 
as the first step of the treatment. One of the most 
common and most dangerous complications is the 
anastomotic leak (AL) [5–17]. There are several effec-
tive methods to reduce its risk, the majority of them 
being covered by parts of the ERAS protocol, but 
there only a few which may improve the anastomotic 
healing from a more technical than general point of 
view. One of the key techniques is the protective (or 
‘defunctioning’) loop ileostomy (PLI). It was proven to 
be an effective, yet obviously burdensome procedure 
[18, 19]. The main drawbacks of PLI include reduc-
tion of the patient’s quality of life and increase of 
chemotherapy’s complication rate, often leading to 
dose reduction or regimen modification [20]. Most 
centers restore the continuity of the gastrointesti-
nal tract more than one month after the adjuvant 
chemotherapy is terminated [21]. That approach is 
burdensome not only for patients, whose quality of 
life is significantly lower, but also for the health care 
system, which must cover the direct costs of stoma 
bags and indirect expenses of social inactivity. It also 
contradicts to some extent the ERAS concept of per-
fecting the post-surgical recovery period.
So-called ‘early closure’ (EA) can provide a solution 
to the problem. It can be safely performed within days 
or weeks after the primary surgery and it is an effective 
procedure [22–25]. Undoubtedly, it could be a valuable 
asset to ERAS, yet it has not been recognized that way.
Aim
The aim of the randomized, controlled clinical 
trial was to prove that EA should become a part of 
the routine ERAS approach, as it improves the qual-
ity of life and speeds up recovery, leading either to 
the termination of successful surgical treatment or 
enabling the start of adjuvant treatment. 
Material and methods
A  randomized, controlled clinical trial was per-
formed at two surgical units between October the 
1st, 2016 and December the 31st, 2017. Both centers 
have been using the ERAS protocol in daily routine 
practice for more than 5 years. The compliance 
rate with ERAS guidelines for both of them reaches 
> 90% every year.
Fifty-eight adult rectal cancer patients (24 fe-
males, 34 males, mean age 55.7 and 56.2) with PLI 
created during the low anterior section were ran-
domly assigned to two study groups: early closure 
(E, n = 29), late closure (L, n = 29, control group). 
Randomization was performed before discharge 
from the hospital by a  person not involved in the 
study using sealed envelopes containing comput-
er-generated allocation numbers. No blocking or 
stratification was used.
Inclusion criteria: ≥ 18 years of age, rectal adeno-
carcinoma, anterior resection of the rectum with PLI. 
Exclusion criteria: colorectal malignancy other than 
rectal adenocarcinoma, PLI performed for other indi-
cations (for example as part of treatment for postop-
erative complication), lack of informed consent. 
Patients were well matched with regard to age, 
gender, nutritional status (BMI), and diagnosis. De-
tailed characteristics are presented in Table I.
All patients were treated with neoadjuvant radio-
chemotherapy (short and long arm) before surgery. 
Surgical complications were described and then pre-
sented using the Clavien-Dindo classification [26].
As the improvement of the quality of life achieved 
by reconstruction of the gastrointestinal tract was 
obvious and does not require any additional studies, 
the working hypothesis assumed that EC is safe and 
does not increase the complication rate (primary 
end point). The secondary objective (secondary end 
point) was to assess the impact of EC on the start of 
postoperative adjuvant anti-cancer treatment. 
It was assumed that the confirmation of the 
complete has to be healing not only clinical, but also 
pathological. The evaluation of all anastomoses was 
performed by a skilled pathologist. 
The surgical technique was the same for both 
groups and was composed of the following phases:
–  excision of the existing stoma,
–  excision of the last 1 cm of the small intestine on 
both sides of resection,
–  end-to-end anastomosis with double layer contin-
uous running suture (Vicryl 4-0),
–  fascia closure with continuous running suture 
(PDS II, 0),
–  skin wound closure.
The postoperative care after both procedures 
was based on the enhanced recovery after surgery 
(ERAS) protocol. Major surgical aspects of ERAS in-
cluded: no drainage, no nasogastric tube, no osmot-
ic bowel preparation, single shot antibiotics 30 min 
before skin incision, mobilization directly after sur-
gery, less than 500 ml of i.v. intravenous fluids on the 
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1st day postoperatively, no opioid-based pain killers. 
The primary rectal resection was performed laparo-
scopically or with open technique after conversion 
due to technical difficulties. All ileo-rectal anastomo-
ses were created using a stapling device (Premium 
Plus CEEA 29, Johnson & Johnson, USA).
Nutritional aspects: beginning of oral food intake 
– 2–4 h after surgery, regular food on postoperative 
day 1. All patients were discharged from hospital be-
tween the 3rd and 5th day.
Timing of the reconstruction:
1) Early closure group: the patient was re-admitted 
to the hospital 14 days after the discharge af-
ter the primary resection. The primary discharge 
took place between the 4th and 6th postoperative 
day. 
2) Late closure group: the patient was re-admitted 
to the hospital 30 days after the termination 
of the adjuvant chemotherapy, usually approxi-
mately 7 months after the primary resection. The 
primary discharge was the same as for the EC 
group.
In all patients the sigmo-rectal anastomosis was 
checked with endoscopy. The distal loop of the pro-
tective stoma was flushed with 1000 ml of saline 
the day before the restoration to prove the effective 
passage of the gastrointestinal tract. 
Ethics and consent
The Ethics Committee of the Jagiellonian 
University Medical School approved the study 
[122.6120.207.2016]. Patients were personally en-
rolled and approached by the lead investigators (SK, 
JS). Informed written consent was obtained from 
each participant before enrollment. The study was 
carried out following the international ethical rec-
ommendations stated in the Helsinki Declaration 
and was registered under the number: ClinicalTrials.
gov PRS registration: NCT02997267.
Statistical analysis
All data were analyzed with StatSoft Statistica 
v.12. The results are presented as mean ± stan-
Table I. General characteristics and nutritional parameters
Parameter Early closure (E) Late closure (L) P-value
Number of patients 29 29 –
Females, n (%) 11 (37.9) 13 (44.8) 0.5941
Males, n (%) 18 (62.1) 16 (55.2)
Age, mean ± SD (median) [years] 55.7 ±12.2 (54) 56.2 ±12.5 (58) 0.6217
Stage of cancer, n (%):
IIA 8 (27.6) 9 (31.0) 0.9301
IIB 2 (6.9) 3 (10.3)
IIC 7 (24.1) 5 (17.3)
IIIA 4 (13.8) 3 (10.3)
IIIB 5 (17.3) 4 (13.8)
IIIC 3 (10.3) 5 (17.3)
Median length of hospital stay after primary resection (IQR) [days] 6 (6–7) 6 (5–7) 0.4455
Type of primary surgery, n (%): –
Laparoscopic 26 (89.7) 26 (89.7)
Open (after conversion) 3 (10.3) 3 (10.3)
Neoadjuvant radio-chemotherapy, n (%) 29 (100) 29 (100) –
Adjuvant chemotherapy, n (%) 25 (86.2) 27 (93.1) 0.3884
*c2 test with Yates’ correction.
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dard deviation (SD), median and interquartile 
range (IQR) when appropriate. The study of cate-
gorical variables used the c2 test of independence. 
The Shapiro-Wilk test was used to check for nor-
mal distribution of data. Student’s t-test was used 
for normally distributed quantitative data. For 
non-normally distributed quantitative variables, 
the Kruskal-Wallis test was used. In the next step 
the Friedman test was used for non-normally dis-
tributed dependent variables. Results were consid-
ered statistically significant when the p-value was 
found to be less than 0.05.
To calculate the sample size we decided to use 
the time to start the adjuvant chemotherapy as the 
main parameter. We assumed that a delay of three 
or more weeks at the start of chemotherapy would 
represent a  clinically relevant difference. To detect 
that we calculated that 23 patients would be re-
quired in each treatment arm to give the study the 
power of 90%. 
Results
Fifty-eight patients were fully evaluated; there 
were no drop-outs. The CONSORT diagram shows 
patients’ flow through the study (Figure 1). Neither 
fatal outcomes nor anastomotic leaks were observed 
in either group. Postoperative complications includ-
ed volvulus (group E, n = 1), surgical site infection 
(E = 2, T = 3, p > 0.05) and intraabdominal bleeding 
(group T, n = 1) (Table II).
Time to pass flatus and the first stool was almost 
the same in both groups (2 days for both groups). 
There were no significant differences between the 
two groups regarding either the length of surgery 
(T = 83.2 in E vs. 87.1 min in L, p > 0.05) or intra-
operative blood loss (E = 15.2 ml vs. L = 17.3 ml, 
p > 0.05). The median hospital stay was 5 days in 
both groups (p > 0.05).
The mean time to start adjuvant treatment was 
38.7 ±5.7 and 33.2 ±5.8 days in groups E and L, respec-
tively, which was statistically significant, but without 
any clinical importance, as the adjuvant treatment 
started within 8 weeks after resection. The mean du-
ration of living with a stoma was 17.3 days in group E 
and 278.6 days in group L. The mean health care costs 
(calculated as the cost of stoma bags) per capita per 
period of treatment were: PLN 152.9. in group E and 
PLN 2413.1 group L (USD 43.68 vs. 698.42). A detailed 
description is presented in Table III.
Pathologist’s report
Microscopic examination revealed no significant 
differences between the two groups of patients. In 
Figure 1. CONSORT diagram
Assessed for eligibility (n = 77)Enrollment
Randomized (n = 58)
Allocation
Early closure (n = 29) Late closure (n = 29) 
Analyzed
E group (n = 29) L group (n = 29)
Excluded (n = 19):
– Not meeting inclusion criteria (n = 16)
– Declined to participate (n = 3)








I 2 (SSI) 3 (SSI)
II 0 0
IIIa 0 0
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reviewed slides from group E patients’ signs of acute 
tissue injury were present. Areas of granulation tis-
sue, focal hemorrhages and inflammatory infiltrates 
containing numerous neutrophils located especially 
in the intestinal mucus membrane were observed. 
Tissue samples obtained from group L exhibited 
acute-on-chronic pattern of inflammation. Mono-
nuclear inflammatory infiltrates with various admix-
tures of neutrophils were present in lamina propria 
of the intestinal mucus membrane. In 1 case neu-
trophils entered crypt epithelium and formed clus-
ters in the glandular lumen. Additionally, superficial 
erosions, hyperemia and fibrosis of the submucosal 
membrane were observed. In both groups intestinal 
epithelium and adjacent epidermis focally showed 
slight reactive changes.
Discussion
The ERAS protocol has been the major game- 
changer as far as perioperative care is considered. 
Being a protocol composed of approximately 17 key 
aspects, each improving the clinical outcome, it in-
fluences all facets of surgery. The ERAS has still been 
developing and improving over the years, reaching 
for new areas of improvement, such as the minimal-
ly invasive approach, new combinations of drugs and 
interventions. Practically each new clinical approach 
can be considered as part of the ERAS protocol, as 
long as it speeds up the recovery.
Anastomotic leakage (AL) is a major problem in 
colorectal surgery, particularly in rectal cancers lo-
cated not far from the anal verge [5–9]. It has been 
observed with the frequency ranging from 2.6% to 
19.0% [5–15]. AL is the a  main reason for the in-
crease in the postoperative morbidity, mortality and 
worsening of the quality of life, and it may be a rea-
son for an increase in the local recurrence of rectal 
cancer [5–17].
The protective loop ileostomy was introduced to 
divert the fecal stream from a more distal anastomo-
sis in order to reduce the consequences of any anas-
tomotic leakage [18, 19]. The intervention proved to 
be effective [18, 19].
From patients’ perspective, however, the quality 
of life when living with a stoma cannot be satisfacto-
ry. Therefore the need for gastrointestinal (GI) tract 
reconstruction is unquestionable [20]. The question 
when to do it, however, remains open. As the surgery 
during chemotherapy is burdened with a higher rate 
of complications, almost all surgeons would wait un-
til the adjuvant treatment is terminated. Reasonable 
as it is, that approach exposes the patient to several 
months of living with a stoma, leading to progres-
sive health care costs due to equipment, additional 
medical care and social inactivity.
For these reasons, it would seem judicious to close 
the stoma as early as possible [21–23]. The safety 
and efficacy of the early procedure was confirmed in 
the four-study metaanalysis by Robertson et al. [20]. 
Table III. Clinical outcomes





Patients with complications, n (%) 3 (10.3) 4 (13.8) 0.6873
Time to first flatus, median (IQR) [days] 2 (1–2) 2 (1–2) 0.9431
Time to first defecation, median (IQR) [days] 3 (2–3) 3 (2–3) 0.5934
Length of hospital stay, median (IQR) [days] 5 (4–6) 5 (4–5) 0.6316
Readmission, n (%) 0 0 –
Duration of surgery, mean ± SD [min] 83.2 ±15.9 87.1 ±21.7 0.4967
Perioperative blood loss, mean ± SD [ml] 15.2 ±7.5 17.3 ±11.1 0.7142
Number of stoma bags/treatment period, mean ± SD (median) 19.1 ±2.2 (17) 307.6 ±91.9 (305) < 0.001
Duration of living with stoma, mean ± SD (median) [days] 17.3 ±1.5 (17) 278.6 ±89.1 (250) < 0.001
Cost of stoma bags/treatment period, mean ± SD (median) 152.9 ±16.3 (148) 2413.1 ±759 (2320) < 0.001
Time to start adjuvant chemotherapy, mean ± SD (median) [days] 38.7 ±5.7 (41) 33.2 ±5.8 (31) < 0.001
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EC poses two clinical risks: unsuccessful anastomot-
ic healing and the delay of adjuvant chemotherapy. 
EC allows also to elevate the rectal cancer patient to 
a person of maximally accelerated recovery. 
For many years, however, there was an open is-
sue of the optimal timing; some authors, such as 
Menegaux et al. and Danielsen et al., proposed to 
close it between the 8th and the 13th postoperative 
day [22, 23]. None of them, however, presented ei-
ther the precise timing or the rationale for that time 
period [24].
The first question was solved by the study of 
Marjnovic and Hopt [25]. These authors demonstrat-
ed that the healing process is composed of three 
phases: inflammatory, proliferative and reparatory 
[25]. The first phase (postoperative days 1 to 4; POD 
1–4) is dominated by inflammation, migration of im-
mune cells and the activity of mucosa, and for these 
reasons it is mostly surgical technique dependent. 
The second (POD 5–14) is mostly based on collagen 
formation and angiogenesis, and decides about the 
quality of the juncture [25]. During the third one (up 
to 12 months after surgery), the re-modeling of the 
anastomosis takes place.
From the clinical point of view, the first two 
phases are the most important, and when they are 
finished, the anastomosis is safe. In our study there 
was a small difference in the time needed to start 
the adjuvant treatment (38.7 vs. 33.2 days, p < 0.01). 
Nonetheless, as the adjuvant chemotherapy should 
start not later than 8 weeks after surgery, because 
the later one may lead to a decrease of 5-year sur-
vival rates [26–29], the difference observed in our 
study was insignificant from the clinical perspective. 
Therefore, if EC is supposed to be a reliable clinical 
option, it can be performed within a few weeks af-
ter the primary resection. Thanks to studies on En-
hanced Recovery After Surgery (ERAS) protocols, the 
primary discharge can take place on POD 4 to 6 [30–
32], enabling fortnight readmission for EC. 
The current study proved that EC can be safe (no 
differences in the rate of complications, length of 
stay) and effective (almost the same time to pass 
flatus and stool, no fistulization).
Pathological examination did not reveal major 
differences between groups, which confirmed that 
the healing process was already accomplished. It 
was reflected in technical considerations: the dura-
tion of surgery and intraoperative blood loss were 
the same. 
The 14-day post-discharge GI restoration led to 
significant health care savings – mean health care 
costs per capita per period of treatment were: PLN 
136.1 in group E and PLN 2440.0 in group L (34 vs. 
610 USD). Moreover, the reduction of stoma days 
resulted in higher quality of life and facilitated the 
uncomplicated course of adjuvant chemotherapy, 
which started not later than 6 weeks after primary 
surgery. 
Conclusions
Early closure of protective ileostomy is a safe and 
effective therapeutic approach. It allows one to re-
duce health care costs and improve the quality of 
life, not exposing the further treatment to a risk of 
failure. For the above reasons it should be imple-
mented as part of the ERAS protocol for rectal cancer 
patients. 
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